EIKOSpecialty Chemicals
Eiko Lifesciences Ltd — Profit & Loss Statement
₹49.74
-3.48%
Eiko Lifesciences Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.09 Cr | 0.00 | 79041.61 | 0.00 | — |
| Tax Rate For Calcs | 0.24 | 0.24 | 0.25 | 0.25 | — |
| Normalized EBITDA | 3.59 Cr | 1.79 Cr | 1.78 Cr | 1.87 Cr | — |
| Total Unusual Items | 0.36 Cr | 0.00 | 0.03 Cr | — | 0.00 |
| Total Unusual Items Excluding Goodwill | 0.36 Cr | 0.00 | 0.03 Cr | — | 0.00 |
| Net Income From Continuing Operation Net Minority Interest | 2.11 Cr | 0.75 Cr | 0.77 Cr | 0.71 Cr | — |
| Reconciled Depreciation | 0.74 Cr | 0.30 Cr | 0.63 Cr | 0.56 Cr | — |
| Reconciled Cost Of Revenue | 32.66 Cr | 25.64 Cr | 16.64 Cr | 23.32 Cr | — |
| EBITDA | 3.96 Cr | 1.79 Cr | 1.81 Cr | 1.87 Cr | — |
| EBIT | 3.22 Cr | 1.13 Cr | 1.18 Cr | 1.31 Cr | — |
| Net Interest Income | 0.53 Cr | 0.04 Cr | 0.57 Cr | 0.16 Cr | — |
| Interest Expense | 0.15 Cr | 0.14 Cr | 0.15 Cr | 0.37 Cr | — |
| Interest Income | 0.69 Cr | 0.18 Cr | 0.73 Cr | 0.64 Cr | — |
| Normalized Income | 1.83 Cr | 0.75 Cr | 0.75 Cr | 0.71 Cr | — |
| Net Income From Continuing And Discontinued Operation | 2.11 Cr | 0.75 Cr | 0.77 Cr | 0.71 Cr | — |
| Total Expenses | 34.94 Cr | 26.98 Cr | 17.99 Cr | 24.62 Cr | — |
| Rent Expense Supplemental | 0.36 Cr | 0.04 Cr | 0.07 Cr | 0.00 | — |
| Diluted Average Shares | 1.30 Cr | 1.03 Cr | 0.98 Cr | 0.90 Cr | — |
| Basic Average Shares | 1.30 Cr | 1.03 Cr | 0.98 Cr | 0.90 Cr | — |
| Diluted EPS | 1.62 | 0.73 | 0.79 | 0.78 | — |
| Basic EPS | 1.62 | 0.73 | 0.79 | 0.78 | — |
| Diluted NI Availto Com Stockholders | 2.11 Cr | 0.75 Cr | 0.77 Cr | 0.71 Cr | — |
| Net Income Common Stockholders | 2.11 Cr | 0.75 Cr | 0.77 Cr | 0.71 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 2.11 Cr | 0.75 Cr | 0.77 Cr | 0.71 Cr | — |
| Minority Interests | -0.21 Cr | — | — | — | — |
| Net Income Including Noncontrolling Interests | 2.32 Cr | 0.75 Cr | 0.77 Cr | 0.71 Cr | — |
| Net Income Continuous Operations | 2.32 Cr | 0.75 Cr | 0.77 Cr | 0.71 Cr | — |
| Tax Provision | 0.75 Cr | 0.23 Cr | 0.26 Cr | 0.24 Cr | — |
| Pretax Income | 3.06 Cr | 0.98 Cr | 1.03 Cr | 0.94 Cr | — |
| Other Non Operating Income Expenses | 0.93 Cr | 0.18 Cr | 0.85 Cr | 0.02 Cr | — |
| Special Income Charges | 0.34 Cr | — | — | — | — |
| Other Special Charges | -0.34 Cr | — | — | — | — |
| Net Non Operating Interest Income Expense | 0.53 Cr | 0.04 Cr | 0.57 Cr | 0.16 Cr | — |
| Total Other Finance Cost | 0.01 Cr | 34000.00 | 60000.00 | 0.11 Cr | — |
| Interest Expense Non Operating | 0.15 Cr | 0.14 Cr | 0.15 Cr | 0.37 Cr | — |
| Interest Income Non Operating | 0.69 Cr | 0.18 Cr | 0.73 Cr | 0.64 Cr | — |
| Operating Income | 1.10 Cr | 0.95 Cr | 0.33 Cr | 0.81 Cr | — |
| Operating Expense | 2.27 Cr | 1.34 Cr | 1.36 Cr | 1.30 Cr | — |
| Other Operating Expenses | 1.00 Cr | 0.01 Cr | 0.03 Cr | 0.03 Cr | — |
| Depreciation And Amortization In Income Statement | 0.74 Cr | 0.66 Cr | 0.63 Cr | 0.56 Cr | — |
| Depreciation Income Statement | 0.74 Cr | 0.66 Cr | 0.63 Cr | 0.56 Cr | — |
| Selling General And Administration | 0.20 Cr | 0.40 Cr | 0.34 Cr | 0.42 Cr | — |
| Selling And Marketing Expense | 0.03 Cr | 0.01 Cr | 61000.00 | 0.03 Cr | — |
| General And Administrative Expense | 0.17 Cr | 0.39 Cr | 0.33 Cr | 0.40 Cr | — |
| Rent And Landing Fees | 0.36 Cr | 0.04 Cr | 0.07 Cr | 0.00 | — |
| Gross Profit | 3.37 Cr | 2.29 Cr | 1.69 Cr | 2.11 Cr | — |
| Cost Of Revenue | 32.66 Cr | 25.64 Cr | 16.64 Cr | 23.32 Cr | — |
| Total Revenue | 36.03 Cr | 27.93 Cr | 18.32 Cr | 25.43 Cr | — |
| Operating Revenue | 36.03 Cr | 27.93 Cr | 18.32 Cr | 25.43 Cr | — |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Eiko Lifesciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.